USFDA raises concern over drug production process at Cadila

Tags: News
The US Food and Drug Administration (FDA) has expressed concerns over the manufacturing process of at least one product at drugmaker Cadila Healthcare Ltd's Moraiya facility, two sources with direct knowledge of the matter said.

The FDA has not expressed concerns over the entire facility, said the sources. The US agency communicated its concern to Cadila in a Form 483, a letter in which the agency typically outlines violations of standard manufacturing practices.

Once the Form 483 is sent, the company has 15 days to respond before the FDA takes any further action.

The FDA inspected the Moraiya plant, based in Gujarat, in the second week of July, one of the sources said.

The sources declined to be named as the information is not public yet. A Cadila spokeswoman declined to comment.

Cadila's shares dropped as much as 10.5% on Thursday and were trading down 5.3% to Rs 1,106.50 at 1:01 pm., while the broader Nifty was down 0.22%.

EDITORIAL OF THE DAY

  • Dictating retail price of a commodity goes against the grain of free market economy

    The Centre’s suggestion to states to cap prices of pulses and edible oils seems to indicate a bankruptcy of ideas in the government.

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Susan Visvanathan

Tracing societies through biographies

Memory is thought to be multilayered and interactive. Small ...

Rajgopal Nidamboor

The real truth about happiness

Happiness is a monumental question with no easy answers. It ...

Dharmendra Khandal

When it rains, this beetle starts rolling dung

On the buffer road of a forest, a small metallic ...